Description
A 12-month prospective study in obese, newly diagnosed Type 2 diabetes patients showed that vildagliptin added to metformin achieved >1% HbA1c reduction in 86.5% of patients, with additional benefits on body weight and homocysteine, a key cardiovascular risk marker.